Biologics, drugs that are produced from living organisms, have revolutionized the pharmaceutical industry with their ability to target specific disease-causing proteins. However, developing biologics can be challenging due to the complexity of producing and delivering them to patients. That’s where Richter Helm technology comes in.
Richter Helm Technology:
Richter Helm is a leading contract development and manufacturing organization (CDMO) that specializes in biologics. Their technology platform includes a variety of innovative systems that enable efficient production and delivery of biologics.
One such system is the Single-Use Bioreactor (SUB), which allows for flexible manufacturing of biologics without the need for large-scale facilities. SUBs are scalable, easy-to-use, and cost-effective.
Another key technology offered by Richter Helm is their expertise in protein purification. The company has developed novel methods for purifying biologic proteins that allow for higher yields and improved quality.
Richter Helm technology has been used to develop a variety of products including monoclonal antibodies, fusion proteins, and vaccines.
One notable application of Richter Helm’s technology is their work with COVID-19 vaccines. The company partnered with an mRNA vaccine developer to provide manufacturing support for the COVID-19 vaccine candidate. Their expertise in both upstream and downstream processing allowed for efficient production of the vaccine at scale.
In addition to vaccine development, Richter Helm’s technology has been used in the production of cancer therapies, enzyme replacements therapies, and more.
Richter Helm’s innovative technology platform has revolutionized biologics development by enabling efficient production and delivery of these complex drugs. Their contributions to vaccine development during the COVID-19 pandemic have underscored their importance in advancing healthcare through biologics.